Page 702 - Read Online

Peiró et al. J Cancer Metastasis Treat 2019;5:49 I http://dx.doi.org/10.20517/2394-4722.2018.109 Page 11 of
11
34. Zhong R, Xu H, Chen G, Zhao G, Gao Y, et al. The role of hypoxia-inducible factor-1α in radiation-induced autophagic cell death in
breast cancer cells. Tumour Biol 2015;36:7077.
35. Li X, Wu Y, Liu A, Tang X. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-
HIF1α feedback regulatory loop. Tumour Biol 2016;37:14733-43.
36. Li G, Shan C, Liu L, Zhou T, Zhou J, et al. Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/
p70S6K/RPS6/4E-BP1 signaling pathway. PLoS One 2015;10:e0117440.
37. Cho KH, Yu SL, Cho DY, Park CG, Lee HY. Breast cancer metastasis suppressor 1 (BRMS1) attenuates TGF-β1-induced breast cancer
cell aggressiveness through downregulating HIF-1α expression. BMC Cancer 2015;15:829.
38. Wang F, Chang M, Shi Y, Jiang L, Zhao J, et al. Down-regulation of hypoxia-inducible factor-1 suppresses malignant biological behavior
of triple-negative breast cancer cells. Int J Clin Exp Med 2014;7:3933-40.
39. Shao C, Zhang J, Fu J, Ling F. The potential role of Brachyury in inducing epithelial-to-mesenchymal transition (EMT) and HIF-1a
expression in breast cancer cells. Biochem Biophys Res Commun 2015;467:1083-89.
40. Fu P, Du F, Chen W, Yao M, Lv K, et al. Tanshinone IIA blocks epithelial-mesenchymal transition through HIF-1α downregulation,
reversing hypoxia-induced chemotherapy resistance in breast cancer cell lines. Oncol Rep 2014;31:2561-68.
41. Li Z, Zhu Q, Hu L, Chen H, Wu Z, et al. Anterior gradient 2 is a binding stabilizer of hypoxia inducible factor-1α that enhances CoCl2
-induced doxorubicin resistance in breast cancer cells. Cancer Sci 2015;106:1041-49.
42. Xu S, Liu P. Tanshinone II-A: new perspectives for old remedies. Expert Opin Ther Pat. 2013;23:149-53.
43. von Wahlde MK, Hülsewig C, Ruckert C, Götte M, Kiesel L, et al. The anti-androgen drug dutasteride renders triple negative breast
cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling. Gynecol Endocrinol 2015;31:160-64.
44. Luo HQ, Xu M, Zhong WT, Cui ZY, Liu FM, et al. EGCG decreases the expression of HIF-1α and VEGF and cell growth in MCF-7
breast cancer cells. J BUON 2014;19:435-39.
45. Yang H, Xia Q, Zou Y, Wang K, Jiang W, et al. M410, a combretastatin A4 analogue, disrupts microtubules and inhibits HIF-1α in human
breast cancer cells. Oncol Rep 2015;34:334-40.
46. Ghattass K, El-Sitt S, Zibara K, Rayes S, Haddadin MJ, et al. The quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro
and in vivo by targeting the hypoxia inducible factor-1 pathway. Mol Cancer 2014;13:12-24.
47. Liu Y, Zhang J, Sun X, Li M. EMMPRIN down-regulating miR-106a/b modifies breast cancer stem-like cell properties via interaction
with fibroblasts through STAT3 and HIF-1α. Sci Rep 2016;6:28329.
48. Pakravan K, Babashah S, Sadeghizadeh M, Mowla SJ, Mossahebi-Mohammadi M, et al. MicroRNA-100 shuttled by mesenchymal stem
cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1α/VEGF signaling axis in breast cancer
cells. Cell Oncol 2017;40: 457-70.
49. Kuo CY, Cheng CT, Hou P, Lin YP, Ma H, et al. HIF-1-alpha links mitochondrial perturbation to the dynamic acquisition of breast
cancer tumorigenicity. Oncotarget 2016;7:34052-69.
50. Tosatto A, Sommaggio R, Kummerow C, Bentham RB, Blacker TS, et al. The mitochondrial calcium uniporter regulates breast cancer
progression via HIF-1α. EMBO Mol Med 2016;8:569-85.
51. Zhu X, Li Q, Li S, Chen B, Zou H. HIF-1α decoy oligodeoxynucleotides inhibit HIF-1α signaling and breast cancer proliferation. Int J
Oncol 2015;46:215-22.
52. Wei L, Zhou Y, Qiao C, Ni T, Li Z, et al. Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting
SIRT3-mediated SOD2 transcription and HIF1α destabilization. Cell Death Dis 2015;6:e1714.
53. Jeong YJ, Cho HJ, Magae J, Lee IK, Park KG et al. Ascofuranone suppresses EGF-induced HIF-1α protein synthesis by inhibition of the
Akt/mTOR/ p70S6K pathway in MDA-MB-231 breast cancer cells. Toxicol. Appl. Pharmacol 2013;273:542-50.
54. Qiu SP, Li HL, Shi HL, Wu H, Huang F, et al. Notoginsenoside Ft1 down-regulates HIF-1α, inhibits cell proliferation, decreases
migration and promotes apoptosis in breast cancer cells. Yao Xue Xue Bao 2016;51:1091-97. (in Chinese).
55. Li J, Zhang C, Jiang H, Cheng J. Andrographolide inhibits hypoxia-inducible factor-1 through phosphatidylinositol 3-kinase/AKT
pathway and suppresses breast cancer growth. Onco Targets Ther 2015;8:427-35.
56. Esfandiary A, Taherian-Esfahani Z, Abedin-Do A, Mirfakhraie R, Shirzad M, et al. Lactobacilli modulate hypoxia-inducible factor
(HIF)-1 regulatory pathway in triple negative breast cancer cell line. Cell J 2016;18:237-44.
57. Wei Z, Shan Y, Tao L, Liu Y, Zhu Z, et al. Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIF-1α synthesis, and
decreases breast cancer metastasis. Mol Carcinog 2017;56:2317-31.
58. Pan Y, Shao D, Zhao Y, Zhang F, Zheng X, et al. Berberine reverses hypoxia-induced chemoresistance in breast cancer through the
inhibition of AMPK-HIF-1α. Int J Biol Sci 2017;13:794-803.